Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Deep Dutta 2 Articles
Diabetes, obesity and metabolism
Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
A.B.M. Kamrul-Hasan, Muhammad Shah Alam, Samir Kumar Talukder, Deep Dutta, Shahjada Selim
Endocrinol Metab. 2024;39(1):109-126.   Published online January 23, 2024
DOI: https://doi.org/10.3803/EnM.2023.1839
  • 1,661 View
  • 63 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
No recent meta-analysis has holistically analyzed and summarized the efficacy and safety of omarigliptin in type 2 diabetes mellitus (T2DM). We conducted a meta-analysis to address this knowledge gap.
Methods
Electronic databases were searched to identify randomized controlled trials (RCTs) that included patients with T2DM who received omarigliptin in the intervention arm. The control arm consisted of either a placebo (passive control group [PCG]) or an active comparator (active control group [ACG]). The primary outcome assessed was changes in hemoglobin A1c (HbA1c), while secondary outcomes included variations in glucose levels, achievement of glycemic targets, adverse events (AEs), and hypoglycemic events.
Results
From 332 initially screened articles, data from 16 RCTs involving 8,804 subjects were analyzed. Omarigliptin demonstrated superiority over placebo in reducing HbA1c levels (mean difference, –0.58%; 95% confidence interval, –0.75 to –0.40; P<0.00001; I2=91%). Additionally, omarigliptin outperformed placebo in lowering fasting plasma glucose, 2-hour postprandial glucose, and in the percentage of participants achieving HbA1c levels below 7.0% and 6.5%. The glycemic efficacy of omarigliptin was similar to that of the ACG across all measures. Although the omarigliptin group experienced a higher incidence of hypoglycemic events compared to the PCG, the overall AEs, serious AEs, hypoglycemia, and severe hypoglycemia were comparable between the omarigliptin and control groups (PCG and ACG).
Conclusion
Omarigliptin has a favorable glycemic efficacy and safety profile for managing T2DM.

Citations

Citations to this article as recorded by  
  • Role of flibanserin in managing hypoactive sexual desire disorder in women: A systematic review and meta-analysis
    A.B.M. Kamrul-Hasan, Mohammad Abdul Hannan, Muhammad Shah Alam, Fatema Tuz Zahura Aalpona, Lakshmi Nagendra, Shahjada Selim, Deep Dutta
    Medicine.2024; 103(25): e38592.     CrossRef
Close layer
Clinical Study
Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis
Deep Dutta, Anshita Agarwal, Indira Maisnam, Rajiv Singla, Deepak Khandelwal, Meha Sharma
Endocrinol Metab. 2021;36(2):374-387.   Published online April 6, 2021
DOI: https://doi.org/10.3803/EnM.2020.818
  • 6,938 View
  • 233 Download
  • 20 Web of Science
  • 29 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
No meta-analysis has holistically analysed and summarised the efficacy and safety of gemigliptin in type 2 diabetes. The meta-analysis addresses this knowledge gap.
Methods
Electronic databases were searched for randomised controlled trials (RCTs) involving diabetes patients receiving gemigliptin in the intervention arm and placebo/active comparator in the control arm. The primary outcome was change in haemoglobin A1c (HbA1c). The secondary outcomes were alterations in glucose, glycaemic targets, lipids, insulin resistance, and adverse events.
Results
Data from 10 RCTs involving 1,792 patients were analysed. Four had an active control group (ACG), with metformin/dapagliflozin/sitagliptin/glimepiride as the active comparator; six had a passive control group (PCG), with placebo/rosuvastatin as controls. HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], –0.06 to 0.23; P=0.24; I2=0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, –0.91%; 95% CI, –1.18 to –0.63); P<0.01; I2=89%; high certainty of evidence [HCE]). Gemigliptin was superior to PCG regarding achieving HbA1c <7% (12 weeks: odds ratio [OR], 5.91; 95% CI, 1.34 to 26.08; P=0.02; I2=74%; 24 weeks: OR, 4.48; 95% CI, 2.09 to 9.60; P<0.01; I2=69%; HCE). Gemigliptin was comparable to ACG regarding achieving HbA1c <7% after 24 weeks (OR, 0.92; 95% CI, 0.52 to 1.63; P=0.77; I2=66%; MCE). Adverse events were similar between the gemigliptin and control groups (risk ratio [RR], 1.06; 95% CI, 0.82 to 1.36; P=0.66; I2=35%; HCE). The gemigliptin group did not have increased hypoglycaemia (RR, 1.19; 95% CI, 0.62 to 2.28; P=0.61; I2=19%; HCE).
Conclusion
Gemigliptin has good glycaemic efficacy and is well-tolerated over 6 months of use.

Citations

Citations to this article as recorded by  
  • Hyperprolactinemia Due to Prolactinoma has an Adverse Impact on Bone Health with Predominant Impact on Trabecular Bone: A Systematic Review and Meta-Analysis
    Lakshmi Nagendra, Deep Dutta, Sunetra Mondal, Nitin Kapoor, Ameya Joshi, Saptarshi Bhattacharya
    Journal of Clinical Densitometry.2024; 27(1): 101453.     CrossRef
  • Impact of early initiation of ezetimibe in patients with acute coronary syndrome: A systematic review and meta-analysis
    Kunal Mahajan, Lakshmi Nagendra, Anil Dhall, Deep Dutta
    European Journal of Internal Medicine.2024; 124: 99.     CrossRef
  • Efficacy and safety of dorzagliatin, a novel glucokinase activators, in the treatment of T2DM: A meta-analysis of randomized controlled trials
    Yuqian Wu, Kai Wang, Jingyang Su, Xin Liu
    Medicine.2024; 103(8): e36916.     CrossRef
  • Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis
    Deep Dutta, Lakshmi Nagendra, Ameya Joshi, Suryashri Krishnasamy, Meha Sharma, Naresh Parajuli
    Obesity Surgery.2024; 34(5): 1653.     CrossRef
  • Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis
    Deep Dutta, Lakshmi Nagendra, Beatrice Anne, Manoj Kumar, Meha Sharma, A. B. M. Kamrul‐Hasan
    Obesity Science & Practice.2024;[Epub]     CrossRef
  • Safety and tolerability of sodium-glucose cotransporter-2 inhibitors in children and young adults: a systematic review and meta-analysis
    Lakshmi Nagendra, Deep Dutta, Harish Bukkasagar Girijashankar, Deepak Khandelwal, Tejal Lathia, Meha Sharma
    Annals of Pediatric Endocrinology & Metabolism.2024; 29(2): 82.     CrossRef
  • Impact of pheochromocytoma or paraganglioma on bone metabolism: A systemic review and meta-analysis
    Deep Dutta, Lakshmi Nagendra, Manju Chandran, Meha Sharma, Saptarshi Bhattacharya, Satinath Mukhopadhyay
    Journal of Clinical Densitometry.2024; 27(3): 101501.     CrossRef
  • Long-Term Impact on Offspring (5 to 11 Years of Age) of Metformin Use in Pregnancy in Mothers With Diabetes: A Systematic Review and Meta-Analysis
    Deep Dutta, Meha Sharma, Lakshmi Nagendra, Saptarshi Bhattacharya, Ritin Mohindra, Chittaranjan S. Yajnik
    Endocrine Practice.2024;[Epub]     CrossRef
  • Efficacy and Safety of Osilodrostat in Managing Cushing’s Syndrome: A Systematic Review and Meta-Analysis
    Lakshmi Nagendra, Deep Dutta, Nishant Raizada, Vineet Surana, Chitra Selvan, Saptarshi Bhattacharya
    Indian Journal of Endocrinology and Metabolism.2024; 28(3): 232.     CrossRef
  • Efficacy and safety of novel dual glucokinase activator dorzagliatin in type-2 diabetes A meta-analysis
    Deep Dutta, Deepak Khandelwal, Manoj Kumar, Meha Sharma
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102695.     CrossRef
  • Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis
    Deep Dutta, Saptarshi Bhattacharya, Manoj Kumar, Priyankar K. Datta, Ritin Mohindra, Meha Sharma
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102697.     CrossRef
  • Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study
    Soo Lim, Minji Sohn, Jose C. Florez, Michael A. Nauck, Jiyoung Ahn
    Nutrients.2023; 15(1): 248.     CrossRef
  • Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes
    R. Pelluri, S. Kongara, V. R. Nagasubramanian, S. Mahadevan, J. Chimakurthy
    Journal of Endocrinological Investigation.2023; 46(5): 855.     CrossRef
  • Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study
    Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S
    Diabetes & Metabolism.2023; 49(4): 101440.     CrossRef
  • Verapamil improves One-Year C-Peptide Levels in Recent Onset Type-1 Diabetes: A Meta-Analysis
    Deep Dutta, Lakshmi Nagendra, Nishant Raizada, Saptarshi Bhattacharya, Meha Sharma
    Indian Journal of Endocrinology and Metabolism.2023; 27(3): 192.     CrossRef
  • Role of novel sodium glucose co-transporter-2 inhibitor enavogliflozin in type-2 diabetes: A systematic review and meta-analysis
    Deep Dutta, B.G. Harish, Beatrice Anne, Lakshmi Nagendra
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(8): 102816.     CrossRef
  • Semaglutide and cancer: A systematic review and meta-analysis
    Lakshmi Nagendra, Harish BG, Meha Sharma, Deep Dutta
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(9): 102834.     CrossRef
  • Efficacy and Safety of Novel Thiazolidinedione Rivoglitazone in Type-2 Diabetes a Meta-Analysis
    Deep Dutta, Jyoti Kadian, Indira Maisnam, Ashok Kumar, Saptarshi Bhattacharya, Meha Sharma
    Indian Journal of Endocrinology and Metabolism.2023; 27(4): 286.     CrossRef
  • Impact of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome: A systematic review meta-analysis
    Lakshmi Nagendra, Kunal Mahajan, Gunjan Gupta, Deep Dutta
    Indian Heart Journal.2023; 75(6): 416.     CrossRef
  • Optimal use of once weekly icodec insulin in type-2 diabetes: An updated meta-analysis of phase-2 and phase-3 randomized controlled trials
    Deep Dutta, Lakshmi Nagendra, Sowrabha Bhat, Ritin Mohindra, Vineet Surana, Anoop Misra
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(10): 102877.     CrossRef
  • Impact of Enhanced External Counter-pulsation Therapy on Glycaemic Control in People With Prediabetes and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
    Lakshmi Nagendra, Deep Dutta, Meha Sharma, Harish Bg
    touchREVIEWS in Endocrinology.2023; 19(2): 8.     CrossRef
  • Role of Novel Glucagon-like Peptide-1 Receptor Analogue Polyethylene Glycol Loxenatide in Type 2 Diabetes: A Systematic Review and Meta-analysis
    Deep Dutta, Subhankar Chatterjee, Priyankar K. Datta, Ritin Mohindra, Meha Sharma
    Indian Journal of Endocrinology and Metabolism.2023; 27(5): 377.     CrossRef
  • Efficacy and Safety of Ultra-rapid Lispro Insulin in Managing Type-1 and Type-2 Diabetes: A Systematic Review and Meta-Analysis
    Deep Dutta, Lakshmi Nagendra, Saptarshi Bhattacharya, Meha Sharma
    Indian Journal of Endocrinology and Metabolism.2023; 27(6): 467.     CrossRef
  • Safety and efficacy of once weekly dipeptidyl-peptidase-4 inhibitor trelagliptin in type-2 diabetes: A meta-analysis
    Deep Dutta, Ritin Mohindra, Vineet Surana, Meha Sharma
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2022; 16(4): 102469.     CrossRef
  • Efficacy and safety of hydroxychloroquine for managing glycemia in type-2 diabetes: A systematic review and meta-analysis
    D Dutta, R Jindal, D Mehta, M Kumar, M Sharma
    Journal of Postgraduate Medicine.2022; 68(2): 85.     CrossRef
  • Gemigliptin exerts protective effects against doxorubicin-induced hepatotoxicity by inhibiting apoptosis via the regulation of fibroblast growth factor 21 expression
    Kyeong-Min Lee, Yeo Jin Hwang, Gwon-Soo Jung
    Biochemical and Biophysical Research Communications.2022; 626: 135.     CrossRef
  • Reporting and methodological quality of systematic reviews of DPP-4 inhibitors for patients with type 2 diabetes mellitus: an evidence-based mapping
    Zouxi Du, Tingting Lu, Mingdong Gao, Limin Tian
    Acta Diabetologica.2022; 59(12): 1539.     CrossRef
  • Ranirestat improves electrophysiologic but not clinical measures of diabetic polyneuropathy: A meta-analysis
    Deep Dutta, Ritin Mohindra, Manoj Kumar, Ashok Kumar, Meha Sharma
    Indian Journal of Endocrinology and Metabolism.2022; 26(5): 399.     CrossRef
  • Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis
    Deep Dutta, Vineet Surana, Rajiv Singla, Sameer Aggarwal, Meha Sharma
    Indian Journal of Endocrinology and Metabolism.2021; 25(6): 475.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism